申请人:Seattle Children's Hospital (dba Seattle Children's Research Institute)
公开号:US20200087399A1
公开(公告)日:2020-03-19
Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.